>10.3389/fonc.2020.00298 # Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options
- TLR4/MyD88 mediates skeletal muscle wasting: 71, 111

>10.1038/s41416-022-01826-2 # Cancer cachexia: a nutritional or a systemic inflammatory syndrome?
- Systemic inflammation and outcomes in patients: 29-33

>10.3389/fpain.2022.971295 # Cancer cachexia: Pathophysiology and association with cancer-related pain
- Involvement of inflammation in cachexia: 1, 13-15, 16
- Non-inflammatory mediators activin A, myostatin, GDF15, lipocalin-2: 17

>10.1038/s41392-021-00791-1 # JAK/STAT signaling pathway: from bench to clinic

>10.1038/s41573-021-00285-3 # Engineering living therapeutics with synthetic biology
- Prosthetic gene network devices: 27, 28
- Reducing immunogenic response to implanted gene network devices: 41-45
- Prosthetic gene network device for cytokines: 38, 39
